1. Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients
- Author
-
Anna Maria Testi, Robin Foà, Stefania Uccini, Salma Abbas Al-Hadad, Sara Mohamed, Amir Fadhil Al-Darraji, Wafa Ablahad Shateh, Alfonso Piciocchi, Maria Luisa Moleti, and Mazin Faisal Al-Jadiry
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Hydrocortisone ,Biopsy ,Leucovorin ,Methylprednisolone ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Asparaginase ,Humans ,Medicine ,Child ,Cyclophosphamide ,Neoplasm Staging ,business.industry ,Lymphoma, Non-Hodgkin ,Remission Induction ,Cytarabine ,Infant ,Hematology ,Long term results ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Lymphoma ,Survival Rate ,Methotrexate ,Treatment Outcome ,Doxorubicin ,Vincristine ,Child, Preschool ,030220 oncology & carcinogenesis ,Iraq ,B-Cell Non-Hodgkin Lymphoma ,Prednisone ,Female ,business ,030215 immunology - Abstract
Since 2000, an adapted LMB 96 protocol was implemented at the Children-Welfare-Teaching-Hospital in Baghdad for the treatment of childhood B-cell non-Hodgkin lymphoma. The first experience (2000-2005) demonstrated efficacy and feasibility of this protocol in Iraq. In 2006, further adjustments were made in an attempt to reduce therapy-related toxicities. The outcome of the second cohort of 190 children (2006-2010) and the comparison with the previous study are hereby reported. Out of the 180 treated patients, 120 achieved a complete response; during treatment 51 died and 9 abandoned. The 60-month overall survival (OS) and event-free survival (EFS) were 64.7 and 56.3%, respectively. No differences were observed in the 24-month OS and EFS between the 2000-2005 and 2006-2010 cohorts (66.3% vs. 65.1%; p = .89 and 53.3% vs. 57.3%; p = .28, respectively). Therapeutic group-B in the second cohort showed better outcome, although not significant, compared to the first one (EFS 62.9% vs. 53.8%; p = .088). Therapy-related mortality remained high.
- Published
- 2019
- Full Text
- View/download PDF